Anti-inflammatory dose doxycycline for the treatment of rosacea

Expert Review of Dermatology

Volumn 2, Issue 5, 2007, Pages 523-531

  Fowler Jr , Joseph F ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Anti inflammatory; Antimicrobial resistance; Doxycycline; Rosacea; Tetracyclines

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CLONIDINE; DOXYCYCLINE; INTERLEUKIN 1BETA; ISOTRETINOIN; MACROLIDE; MATRIX METALLOPROTEINASE; METRONIDAZOLE; MINOCYCLINE; ORACEA; PHENYTOIN; PHOSPHOLIPASE A2; PLACEBO; SULFACETAMIDE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DAIRY PRODUCT; DEMODEX; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; HYPERSENSITIVITY REACTION; LIPID DIET; LONG TERM CARE; LUPUS LIKE SYNDROME; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN EXPRESSION; REVIEW; RHINOPHARYNGITIS; ROSACEA; SINGLE DRUG DOSE; TREATMENT DURATION; VAGINA CANDIDIASIS;

EID: 35948994955     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.5.523     Document Type: Review

References (58)

1. Wilkin J, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J. Am. Acad. Dermatol. 50, 907-912 (2004).
2. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2, 43-47 (2003).
3. Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis 73, 5-8 (2004).
4. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am. Fam. Physician. 66, 435-440 (2002).
5. Powell FC. Clinical practice. Rosacea. N. Engl. J. Med. 352, 793-803 (2005).
6. Sobye F. Aetiology and pathogenesis of rosacea. Acta Derm. Venereol. 30, 137-158 (1950).
7. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm. Venereol. 69, 419-423 (1989).
8. Baldwin HE. Oral therapy for rosacea. J. Drugs Dermatol. 5, 16-21 (2006).
9. Oztas MO, Balk M, Ogus E et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin. Exp. Dermatol. 28, 188-192 (2003).
10. Maatta M, Kari O, Tervahartiala T et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea - treatment effect of oral doxycycline. Graefes Arch. Clin. Exp. Ophthamol. 244, 957-962 (2006).
11. Smith JR, Lanier VB, Braziel RM et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br. J. Ophthalmol. 91, 226-229 (2007).
12. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv. Ther. 18, 237-243 (2001).
13. Crawford GH, Pelle MT, James WD. Rosacea: I: Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol. 51, 327-341 (2004).
14. Robinson TW. Demodex folliculorum and rosacea. A clinical and histological study. Arch. Dermatol. 92, 542-544 (1965).
15. Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J. Am. Acad. Dermatol. 28, 443-448 (1993).
16. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch. Dermatol. Res. 283, 162-166 (1991).
17. Nally JB, Berson DS. Topical therapies for rosacea. J. Drugs Dermatol. 5, 23-26 (2006).
18. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J. Am. Acad. Dermatol. 56, 107-115 (2007)
19. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized Phase III studies. J. Am. Acad. Dermatol. 48, 836-845 (2003).
20. Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int. J. Dermatol. 36, 942-946 (1997).
21. Bakar O, Demircay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin. Exp. Dermatol. 32, 197-200 (2007).
22. Plewig G, Schopf E. Anti-inflammatory effects of antimicrobial agents: an in vivo study. J. Invest. Dermatol. 65, 532-536 (1975).
23. Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis 74, 118-122 (2004).
24. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J. Clin. Microbiol. 44, 3213-3217 (2006).
25. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch. Dermatol. 132, 934-939 (1996).
26. Francke EL, Neu HC. Chloramphenicol and tetracyclines. Med. Clin. North Am. 71, 1155-1168 (1987).
27. Passier A, Smits-van Herwaarden A, van Puijenbroek E. Photo-onycholysis associated with the use of doxycycline. Br. Med. J. 329, 265 (2004).
28. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin. Microbiol Rev. 5, 387-399 (1992).
29. Nikolowski J, Piewig G. Oral treatment of rosacea. with 13-cis-retinoic-acid. Hautarzt 32, 575-584 (1981).
30. Scheinfeld N, Bangalore S. Facial edema induced by isotretinoin use: a case and a review of the side effects of isotretinoin. J. Drugs Dermatol. 5, 467-468 (2006).
31. Bikowski JB, Goldman MP. Rosacea: where are we now? J. Drugs Dermatol. 3, 251-261 (2004).
32. Walker C, Webster G. A multicenter double-blind, randomized trial to evaluate long-term anti-inflammatory dose doxycycline (40 mg) therapy: results of the lack of effect on bacterial flora. Presented at: Fall Clinical Dermatology Conference. Las Vegas, NV, USA, 7-11 October 2006.
33. Golub LM, Schuler EK, Gallagher BM. New therapeutic uses for an old family of drugs: travels of a dental researcher from the lab to the university's office of technology transfer and beyond. Technol. Health Care. 4, 311-316 (1996).
34. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54, 258-265 (2006).
35. Jones D. Reactive oxygen species and rosacea. Cutis 74(Suppl.) 17-20 (2004).
36. Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol. Online J. 8, 2 (2002).
37. Akamatsu H, Asada M, Komura J, Asada Y, Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm. Venereol. 72, 178-179 (1992).
38. Golub LM, Lee HM, Ryan ME et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 12, 12-26 (1998).
39. Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J. Cell Biochem. 89, 529-538 (2003).
40. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest. Ophthalmol. Vis. Sci. 30, 1569-1575 (1989).
41. Sorsa T Ding Y, Salo T et al. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann. NY Acad. Sci. 732, 112-131 (1994).
42. Golub LM, Wolff M, Roberts S et al. Treating periodontal diseases by blocking tissue-destructive enzymes. J. Am. Dent. Assoc. 125, 163-169 (1994).
43. Amin AR, Attur MG, Thakker GD et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. USA 93, 14014-14019 (1996).
44. Li R, Luo X, Pan Q et al. Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication ha irregular uterine bleeding. Hum. Reprod. 21, 2555-2563 (2006).
45. ®, package insert. CollaGenex Laboratories, PA, USA (2006).
46. CollaGenex Pharmaceuticals, Inc. Data on file.
47. Del Rosso JQ, Webster GF, Jackson M et al. Two randomized Phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J. Am. Acad. Dermatol. 56, 791-802 (2007).
48. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory-dose doxycycline (40-mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Presented at: Winter Clinical Dermatology Conference. Kohala Coast, HI, USA, 12-16 January 2007.
49. Fowler JF. Combined effect of anti-inflammatory dose doxycycline and metronidazole topical gel 1% in the treatment of rosacea. Presented at: 65th Annual Meeting of the American Academy of Dermatology. Washington, DC, USA, 2-6 February 2007.
50. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 48, 411-417 (1991).
51. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2, 234-235 (2003).
52. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch. Dermatol. 139, 467-471 (2003).
53. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 5, 5-13 (2004).
54. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J. Am. Acad. Dermatol. 51, 499-512 (2004).
55. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J. Invest. Dermatol. 86, 449-453 (1986).
56. Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex follicularum and rosacea? J. Eur. Acad. Dermatol. Venereol. 19, 646-647 (2005).
57. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch. Dermatol. 130, 748-752 (1994).
58. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein clearance in ocular rosacea. Invest. Ophthalmol. Vis. Sci. 40, 2506-2512 (1999).